Form 485BXT FIRST TRUST EXCHANGE-TRA

As filed with the Securities and Exchange Commission on March 7, 2025

1933 Act Registration No. 333-210186

1940 Act Registration No. 811-23147

 

United States

Securities and Exchange Commission

Washington, D.C. 20549

Form N-1A
 

Registration Statement Under the Securities Act of 1933	[   ]
Pre-Effective Amendment No. __	[   ]
Post-Effective Amendment No. 565	[X]
and/or
Registration Statement Under the Investment Company Act of 1940	[   ]
Amendment No. 567	[X]

First Trust Exchange-Traded Fund VIII

(Exact name of registrant as specified in charter)

120 East Liberty Drive, Suite 400

Wheaton, Illinois 60187

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, including Area Code: (800) 621-1675

W. Scott Jardine, Esq., Secretary

First Trust Exchange-Traded Fund VIII

First Trust Advisors L.P.

120 East Liberty Drive, Suite 400

Wheaton, Illinois 60187

(Name and Address of Agent for Service)

Copy to:

Eric F. Fess, Esq.

Chapman and Cutler LLP

320 South Canal Street

Chicago, Illinois 60606

It is proposed that this filing will become effective (check appropriate box):

[   ] immediately upon filing pursuant to paragraph (b)

[X] on April 6, 2025 pursuant to paragraph (b)

[   ] 60 days after filing pursuant to paragraph (a)(1)

[   ] on (date) pursuant to paragraph (a)(1)

[   ] 75 days after filing pursuant to paragraph (a)(2)

[   ] on (date) pursuant to paragraph (a)(2) of Rule 485.

If appropriate, check the following box:

[X] this post-effective amendment designates a new effective date for a previously filed post-effective amendment.

 

Contents of Post-Effective Amendment No. 565

This Registration Statement comprises the following papers and contents:

The Facing Sheet

The sole purpose of this filing is to delay the effectiveness of the Registrant’s Post-Effective Amendment No. 561, as it relates to the FT Confluence BDC & Specialty Finance Income ETF, a series of the Registrant, until April 6, 2025. Parts A, B and C of the Registrant’s Post-Effective Amendment No. 547 under the Securities Act of 1933 as it relates to FT Confluence BDC & Specialty Finance Income ETF, filed on November 26, 2024, is incorporated by reference herein.

Signatures

 

Signatures

Pursuant to the requirements of the Securities Act of 1933 and the Investment Company Act of 1940, the Registrant certifies that it meets all of the requirements for effectiveness of this Registration Statement under rule 485(b) under the Securities Act and has duly caused this Registration Statement to be signed on its behalf by the undersigned, duly authorized, in the City of Wheaton, and State of Illinois, on the 7th day of March, 2025.

 

	First Trust Exchange-Traded Fund VIII
	By:	/s/ James M. Dykas
		James M. Dykas, President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the date indicated: 

Signature	Title		Date
/s/ James M. Dykas	President and Chief Executive Officer		March 7, 2025
James M. Dykas
/s/ Derek D. Maltbie	Treasurer, Chief Financial Officer and Chief Accounting Officer		March 7, 2025
Derek D. Maltbie
James A. Bowen*	) Trustee )
	)
Richard E. Erickson*	) Trustee )
	)
Thomas R. Kadlec*	) Trustee )
	)
Denise M. Keefe*	) Trustee )
	)
Robert F. Keith*	) Trustee )
	)	By:	/s/ W. Scott Jardine
Niel B. Nielson*	) Trustee )		W. Scott Jardine Attorney-In-Fact
	)		March 7, 2025
Bronwyn Wright*	) Trustee )
	)

*

Original powers of attorney dated March 14, 2016 or November 1, 2021 or September 11, 2023, authorizing James A. Bowen, W. Scott Jardine, James M. Dykas, Eric F. Fess and Kristi A. Maher to execute Registrant's Registration Statement, and Amendments thereto, for each of the trustees of the Registrant on whose behalf this Registration Statement is filed, were previously executed, filed as an exhibit and are incorporated by reference herein.

 

 

 

 

 

 

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Novo Nordisk's denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
• BTCLOV Launches "Future Light" Global Education Initiative, Committing $18 Million to Advance AI and Web3 Education
• Ukraine's Y-Park Gains Global Recognition as First Dedicated Legal AI Innovation Hub